This is an open label randomized controlled trial for patients with methicillin resistant S. aureus (MRSA) bloodstream infection which will directly compare the two most commonly used therapies, vancomycin and daptomycin.
This study is an approved sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial (NCT05137119)
None
Methicillin-resistant S. aureus bacteremia
Severe allergy or non-severe rash to vancomycin or daptomycin
Suspected or confirmed MRSA pneumonia
Known vancomycin minimum inhibitory concentration (MIC) greater than or equal to 2mg/L or daptomycin MIC greater than or equal to 1mg/L
Todd C. Lee MD MPH FIDSA
Lead sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Sponsor institution
University of Melbourne
Collaborator
The Peter Doherty Institute for Infection and Immunity
Collaborator